ATE445163T1 - Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln - Google Patents

Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln

Info

Publication number
ATE445163T1
ATE445163T1 AT05701698T AT05701698T ATE445163T1 AT E445163 T1 ATE445163 T1 AT E445163T1 AT 05701698 T AT05701698 T AT 05701698T AT 05701698 T AT05701698 T AT 05701698T AT E445163 T1 ATE445163 T1 AT E445163T1
Authority
AT
Austria
Prior art keywords
presidency
assessing
risk
symptoms associated
epcr
Prior art date
Application number
AT05701698T
Other languages
English (en)
Inventor
Santos Jose Hermida
Diaz Ramon Montes
Linares Veronica Hurtado
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of ATE445163T1 publication Critical patent/ATE445163T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05701698T 2004-02-06 2005-02-03 Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln ATE445163T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400269A ES2239532B1 (es) 2004-02-06 2004-02-06 Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
PCT/ES2005/000046 WO2005076000A1 (es) 2004-02-06 2005-02-03 Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr

Publications (1)

Publication Number Publication Date
ATE445163T1 true ATE445163T1 (de) 2009-10-15

Family

ID=34833893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701698T ATE445163T1 (de) 2004-02-06 2005-02-03 Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln

Country Status (12)

Country Link
EP (1) EP1722229B8 (de)
JP (1) JP2007520713A (de)
CN (1) CN1954216A (de)
AT (1) ATE445163T1 (de)
AU (1) AU2005210776A1 (de)
BR (1) BRPI0506635A (de)
CA (1) CA2555783A1 (de)
DE (1) DE602005017016D1 (de)
ES (1) ES2239532B1 (de)
MX (1) MXPA06008799A (de)
RU (1) RU2375716C2 (de)
WO (1) WO2005076000A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
BRPI1013201A2 (pt) 2009-05-05 2019-02-26 Yeda res & development co ltd meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo
AU2011213923A1 (en) * 2010-02-12 2012-08-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Diagnosis of systemic lupus erythematosus (SLE)
JP5960707B2 (ja) * 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
AU2012211537B2 (en) * 2011-02-02 2016-12-08 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anti-carbamylated protein antibodies and the risk for arthritis
RU2586412C2 (ru) * 2012-06-09 2016-06-10 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ оценки риска возникновения патологии беременности
RU2517051C1 (ru) * 2013-01-09 2014-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский государственный университет" (КемГУ) Способ определения вероятности возникновения врожденных пороков развития плода у беременных женщин
CN104655860A (zh) * 2013-11-21 2015-05-27 苏州中赢医疗科技有限公司 一种类风湿性关节炎的诊断标志
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
EP4085252A1 (de) * 2019-12-30 2022-11-09 UNIVERSITÄTSmedizin der Johannes Gutenberg- Universität Mainz Verfahren zum nachweis von pathogenen antiphospholipid-antikörpern und zur identifizierung von inhibitoren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600088B1 (de) * 1992-02-05 1998-12-30 Yamasa Corporation Festphasenreagenz und selbiges verwendendes antikörpertestverfahren
US5804392A (en) * 1997-06-27 1998-09-08 Oklahoma Medical Research Foundation Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide

Also Published As

Publication number Publication date
EP1722229A1 (de) 2006-11-15
WO2005076000A1 (es) 2005-08-18
CN1954216A (zh) 2007-04-25
BRPI0506635A (pt) 2007-05-08
MXPA06008799A (es) 2007-04-17
AU2005210776A1 (en) 2005-08-18
RU2006132064A (ru) 2008-03-20
WO2005076000A8 (es) 2005-10-27
EP1722229B1 (de) 2009-10-07
CA2555783A1 (en) 2005-08-18
EP1722229B8 (de) 2009-11-25
ES2239532A1 (es) 2005-09-16
DE602005017016D1 (de) 2009-11-19
JP2007520713A (ja) 2007-07-26
ES2239532B1 (es) 2006-11-01
RU2375716C2 (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
ATE445163T1 (de) Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln
ATE556030T1 (de) Ultrasensitiver nachweis von analyten
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
ATE405832T1 (de) Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen
DE602007003833D1 (de) Verbesserte vitamin-d-messung
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
DK0820522T3 (da) Assays og indretninger til detektering af ekstrahepatisk galdeatresi
WO2005114218A3 (en) Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
ATE409314T1 (de) Verfahren zur beurteilung rheumatoider arthritis durch messen von anti-ccp und serumamyloid a
ATE514950T1 (de) Verfahren zur untersuchung von sepsis bei menschen
ATE479101T1 (de) Verfahren zur quantifizierung von denaturiertem lipoprotein
SG157244A1 (en) Point of care test for the detection of exposure or immunity to dengue virus
ATE529533T1 (de) Verfahren zum nachweis von analyten in einer probe
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
ATE412181T1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms
DK1991875T3 (da) Test til påvisning af patologiske prioner
ATE520985T1 (de) Verfahren zur bestimmung von antigen und antikörper gegen das antigen
DK1192469T3 (da) Assay
DE69817338D1 (de) Verfahren zum nachweis von autoimmun-pathologien
ATE517344T1 (de) Verfahren zum nachweis des immunisierungszustands einer person
GB2456690A (en) A method for quantitative detection of diabetes related immunological markers
ATE537447T1 (de) Nachweis lipidoxidierender abzyme in proben
JP2013524213A5 (de)
GB0501564D0 (en) Test for prion disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties